SCHEMBL19966728

SCHEMBL19966728

CSC(C)(C)Nc1ccc2nsnc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.49
PTPN11 Q06124 4/20 0.43
PTPN1 P18031 2/20 0.43
MAPT P10636 9/20 0.42
ALDH1A1 P00352 8/20 0.42
MEN1 O00255 7/20 0.42
KMT2A Q03164 7/20 0.42
BLM P54132 5/20 0.42
GAA P10253 4/20 0.42
POLB P06746 3/20 0.42
APAF1 O14727 2/20 0.42
TDP2 O95551 2/20 0.42
CASP3 P42574 2/20 0.42
SENP8 Q96LD8 2/20 0.42
SENP7 Q9BQF6 2/20 0.42
SENP6 Q9GZR1 2/20 0.42
CASP6 P55212 1/20 0.42
ATM Q13315 1/20 0.42
SMN1; SMN2 Q16637 6/20 0.41
NSD2 O96028 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16368599 0.82 KDM4E (0.54) KDM4EPTPN11PTPN1MAPTALDH1A1
SCHEMBL19966687 0.74 KDM4E (0.46) KDM4EPTPN11PTPN1MAPTALDH1A1
SCHEMBL13945662 0.72 KDM4E (0.59) KDM4EPTPN11PTPN1MAPTALDH1A1
SCHEMBL19966690 0.68 PTPN11 (0.60) KDM4EPTPN11PTPN1MAPTALDH1A1
SCHEMBL19091529 0.65 IDO1 (0.40) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2627056 0.65 MEN1 (0.54) KDM4EPTPN11PTPN1MAPTALDH1A1
SCHEMBL4020811 0.63 KDM4E (0.49) KDM4EPTPN11PTPN1MAPTALDH1A1
SCHEMBL31026747 0.63 KDM4E (0.72) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL8315471 0.63 ALDH1A1 (0.56) PTPN1MAPTALDH1A1MEN1KMT2A
SCHEMBL23710307 0.62 KIF11 (0.47) PTPN11ALDH1A1NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227340-B2 Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-03-12 US disclosed
US-20180072712-A1 THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072712-A1 THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS IRAK4, IRAK1, IRAK3 KDM4E 307/4885PTPN11 86/4885PTPN1 68/4885
US-10227340-B2 Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors IRAK4, IRAK1, IRAK3 KDM4E 307/4885PTPN11 86/4885PTPN1 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.